Pharos iBio Co., Ltd. (KOSDAQ:388870)
South Korea · Delayed Price · Currency is KRW 8,510.00
-160.00 (-1.85%)
At close: Feb 13, 2026
Pharos iBio Company Description
Pharos iBio Co., Ltd. engages in the development of treatments for rare and refractory diseases using AI based drug development platform in South Korea.
It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of recurrent ovarian cancer; PHI-501 for refractory solid cancer; PHI-301 for the treatment of refractory lung cancer; and PHI-601 for the treatment of menin inhibitor.
The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.
Pharos iBio Co., Ltd.
| Country | South Korea |
| Founded | 2016 |
| Industry | Pharmaceutical Preparations |
| CEO | Jeong Hyeok Yoon |
Contact Details
Address: 1407&1408, 38, Heungan-daero Anyang-Si South Korea | |
| Phone | 82 3 1345 6170 |
| Website | pharosibio.com |
Stock Details
| Ticker Symbol | 388870 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeong Hyeok Yoon | Chief Executive Officer |
| Sung Won Moon | Chief Financial Officer |